LSP BioVentures

LSP BioVentures refers to a series of funds managed by LSP (Life Sciences Partners), a leading European venture capital firm established in 1998. With a strong focus on the life sciences sector, LSP invested in innovative companies across drug development, medical technology, and digital health. The firm maintained a global presence, with its primary headquarters in Amsterdam and significant offices in Boston (Cambridge, MA), Munich, and San Francisco, underscoring its commitment to both European and North American markets. LSP's investment strategy spanned various stages, from early-stage ventures requiring Series A funding to more mature growth-stage companies.

LSP was known for its deep sector expertise and its ability to identify and nurture promising life sciences companies. Over its history, the firm successfully raised multiple dedicated funds, including the notable LSP BioVentures 6, which closed at €600 million (approximately $690 million USD at the time of its 2019 closing), and LSP BioVentures 7, which secured €1 billion (approximately $1.15 billion USD) in 2021. These substantial fund sizes allowed LSP to make significant commitments to its portfolio companies.

The firm's typical initial investment in a company ranged from €10 million to €30 million, translating to approximately $11.5 million to $34.5 million USD based on a representative exchange rate from the period of these funds' activity. This substantial check size positioned LSP as a significant lead investor capable of providing the capital necessary for ambitious life sciences ventures to advance their research and development. In 2021, LSP was acquired by EQT, a global investment organization, and now operates as EQT Life Sciences, continuing its legacy of investing in transformative life sciences innovations under a new umbrella.